Chronic fatigue syndrome - A neuroimmunological model

Medical Hypotheses

Volumn 77, Issue 1, 2011, Pages 77-83

  Arnett, S V ^a   Alleva, L M ^a   Korossy Horwood, R ^a   Clark, I A ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6 ANTIBODY; PAROXETINE; SERTRALINE;

ALZHEIMER DISEASE; ARTICLE; BRAIN INFECTION; CHRONIC FATIGUE SYNDROME; COGNITIVE THERAPY; ENCEPHALITIS; FIBROMYALGIA; HUMAN; KINESIOTHERAPY; NEUROENDOCRINOLOGY; NONHUMAN; SEX DIFFERENCE;

CENTRAL NERVOUS SYSTEM; FATIGUE SYNDROME, CHRONIC; HUMANS; MODELS, BIOLOGICAL;

EID: 79958053297     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.03.030     Document Type: Article

References (105)

1. Shorter E. Chronic fatigue in historical perspective. Ciba Found Symp 1993, 173:6-16. discussion 16-22.
2. Holmes G.P., Kaplan J.E., Gantz N.M., Komaroff A.L., Schonberger L.B., Straus S.E., et al. Chronic fatigue syndrome: a working case definition. Ann Intern Med 1988, 108:387-389.
3. Jason L.A., Richman J.A., Rademaker A.W., Jordan K.M., Plioplys A.V., Taylor R.R., et al. A community-based study of chronic fatigue syndrome. Arch Intern Med 1999, 159:2129-2137.
4. Fletcher M.A., Zeng X.R., Barnes Z., Levis S., Klimas N.G. Plasma cytokines in women with chronic fatigue syndrome. J Transl Med 2009, 7:96.
5. Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A., et al. International chronic fatigue syndrome study group. Ann Intern Med 1994, 121:953-959.
6. Davenport T.E., Stevens S.R., Baroni K., Van Ness M., Snell C.R. Diagnostic accuracy of symptoms characterising chronic fatigue syndrome. Disabil Rehabil 2011, 6.
7. Hawk C., Jason L.A., Torres-Harding S. Differential diagnosis of chronic fatigue syndrome and major depressive disorder. Int J Behav Med 2006, 13:244-251.
8. Bassi N., Amital D., Amital H., Doria A., Shoenfeld Y. Chronic fatigue syndrome: characteristics and possible causes for its pathogenesis. Isr Med Assoc J 2008, 10:79-82.
9. Zhang L., Gough J., Christmas D., Mattey D.L., Richards S.C., Main J., et al. Microbial infections in eight genomic subtypes of chronic fatigue syndrome/myalgic encephalomyelitis. J Clin Pathol 2009, 63:156-164.
10. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E., et al. Neuro Endocrinol Lett 2009, 30:715-722.
11. Maes M., Mihaylova I., Bosmans E. Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett 2007, 28:456-462.
12. Maes M., Mihaylova I., Kubera M., Uytterhoeven M., Vrydags N., Bosmans E. Coenzyme Q10 deficiency in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 2009, 30:470-476.
13. Ursin H., Eriksen H.R. Sensitization, subjective health complaints, and sustained arousal. Ann N Y Acad Sci 2001, 933:119-129.
14. Cho H.J., Skowera A., Cleare A., Wessely S. Chronic fatigue syndrome: an update focusing on phenomenology and pathophysiology. Curr Opin Psychiatry 2006, 19:67-73.
15. Jason L.A., Helgerson J., Torres-Harding S.R., Carrico A.W., Taylor R.R. Variability in diagnostic criteria for chronic fatigue syndrome may result in substantial differences in patterns of symptoms and disability. Eval Health Prof 2003, 26:3-22.
16. Avellaneda Fernandez A., Perez Martin A., Izquierdo Martinez M., Arruti Bustillo M., Barbado Hernandez F.J., de la Cruz Labrado J., et al. Chronic fatigue syndrome: aetiology, diagnosis and treatment. BMC Psychiatry 2009, 9(Suppl 1):S1.
17. Hickie I., Davenport T., Wakefield D., Vollmer-Conna U., Cameron B., Vernon S.D., et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. Bmj 2006, 333:575.
18. Chia J.K., Chia A. Diverse etiologies for chronic fatigue syndrome. Clin Infect Dis 2003, 36:671-672. author reply 672-673.
19. Koelle D.M., Barcy S., Huang M.L., Ashley R.L., Corey L., Zeh J., et al. Markers of viral infection in monozygotic twins discordant for chronic fatigue syndrome. Clin Infect Dis 2002, 35:518-525.
20. Cairns R., Hotopf M. A systematic review describing the prognosis of chronic fatigue syndrome. Occup Med (Lond) 2005, 55:20-31.
21. Pheley A.M., Melby D., Schenck C., Mandel J., Peterson P.K. Can we predict recovery in chronic fatigue syndrome?. Minn Med 1999, 82:52-56.
22. Van Houdenhove B., Pae C.U., Luyten P. Chronic fatigue syndrome: is there a role for non-antidepressant pharmacotherapy?. Expert Opin Pharmacother 2010, 11:215-223.
23. Luyten P., Van Houdenhove B., Pae C.U., Kempke S., Van Wambeke P. Treatment of chronic fatigue syndrome: findings, principles and strategies. Psychiatry Investig 2008, 5:209-212.
24. Tarkowski E., Liljeroth A.M., Minthon L., Tarkowski A., Wallin A., Blennow K. Cerebral pattern of pro- and anti-inflammatory cytokines in dementias. Brain Res Bull 2003, 61:255-260.
25. Tweedie D., Sambamurti K., Greig N.H. TNF-alpha inhibition as a treatment strategy for neurodegenerative disorders: new drug candidates and targets. Curr Alzheimer Res 2007, 4:378-385.
26. McCoy M.K., Tansey M.G. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation 2008, 5:45.
27. Janelsins M.C., Mastrangelo M.A., Park K.M., Sudol K.L., Narrow W.C., Oddo S., et al. Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol 2008, 173:1768-1782.
28. Gorlovoy P., Larionov S., Pham T.T., Neumann H. Accumulation of tau induced in neurites by microglial proinflammatory mediators. Faseb J 2009, 23:2502-2513.
29. McAlpine F.E., Lee J.K., Harms A.S., Ruhn K.A., Blurton-Jones M., Hong J., et al. Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis 2009, 34:163-177.
30. Medeiros R., Figueiredo C.P., Pandolfo P., Duarte F.S., Prediger R.D., Passos G.F., et al. The role of TNF-alpha signaling pathway on COX-2 upregulation and cognitive decline induced by beta-amyloid peptide. Behav Brain Res 2010, 209:165-173.
31. Clark I.A., Alleva L.M., Vissel B. The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010, 128:519-548.
32. Maes M., Twisk F.N. Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med 2010, 8:35.
33. Koo D. A critical appraisal of the role of Epstein-Barr virus. West J Med 1989, 150:590-596.
34. Shapiro J.S. Does varicella-zoster virus infection of the peripheral ganglia cause Chronic Fatigue Syndrome?. Med Hypotheses 2009, 73:728-734.
35. Thomas M.A., Smith A.P. An investigation of the long-term benefits of antidepressant medication in the recovery of patients with chronic fatigue syndrome. Hum Psychopharmacol 2006, 21:503-509.
36. Chaudhuri A., Behan P.O. Fatigue in neurological disorders. Lancet 2004, 363:978-988.
37. Chia J.K., Chia L.Y. Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome. Clin Infect Dis 1999, 29:452-453.
38. Lerner A.M., Beqaj S.H., Deeter R.G., Fitzgerald J.T. Valacyclovir treatment in Epstein-Barr virus subset chronic fatigue syndrome: thirty-six months follow-up. In Vivo 2007, 21:707-713.
39. Nicolson G.L., Gan R., Haier J. Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. Apmis 2003, 111:557-566.
40. Lorusso L., Mikhaylova S.V., Capelli E., Ferrari D., Ngonga G.K., Ricevuti G. Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 2009, 8:287-291.
41. Gow J.W., Hagan S., Herzyk P., Cannon C., Behan P.O., Chaudhuri A. A gene signature for post-infectious chronic fatigue syndrome. BMC Med Genomics 2009, 2:38.
42. Natelson B.H., Weaver S.A., Tseng C.L., Ottenweller J.E. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin Diagn Lab Immunol 2005, 12:52-55.
43. Aspler A.L., Bolshin C., Vernon S.D., Broderick G. Evidence of inflammatory immune signaling in chronic fatigue syndrome: A pilot study of gene expression in peripheral blood. Behav Brain Funct 2008, 4:44.
44. McDermott C., Richards S.C., Thomas P.W., Montgomery J., Lewith G., et al. A placebo-controlled, double-blind, randomized controlled trial of a natural killer cell stimulant (BioBran MGN-3) in chronic fatigue syndrome. Qjm 2006, 99:461-468.
45. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
46. Van Damme J., Opdenakker G. Interaction of interferons with skin reactive cytokines: from interleukin-1 to interleukin-8. J Invest Dermatol 1990, 95:90S-93S.
47. Nukada Y., Miyazawa M., Kosaka N., Ito Y., Sakaguchi H., Nishiyama N. Production of IL-8 in THP-1 cells following contact allergen stimulation via mitogen-activated protein kinase activation or tumor necrosis factor-alpha production. J Toxicol Sci 2008, 33:175-185.
48. Baraniuk J.N., Casado B., Maibach H., Clauw D.J., Pannell L.K., Hess S.S. A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid. BMC Neurol 2005, 5:22.
49. Schmidt J., Barthel K., Wrede A., Salajegheh M., Bahr M., Dalakas M.C. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008, 131:1228-1240.
50. Goldgaber D., Harris H.W., Hla T., Maciag T., Donnelly R.J., Jacobsen J.S., et al. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci USA 1989, 86:7606-7610.
51. Buxbaum J.D., Liu K.N., Luo Y., Slack J.L., Stocking K.L., Peschon J.J., et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998, 273:27765-27767.
52. Brugg B., Dubreuil Y.L., Huber G., Wollman E.E., Delhaye-Bouchaud N., Mariani J. Inflammatory processes induce beta-amyloid precursor protein changes in mouse brain. Proc Natl Acad Sci USA 1995, 92:3032-3035.
53. Pieczenik S.R., Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol 2007, 83:84-92.
54. Myhill S., Booth N.E., McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med 2009, 2:1-16.
55. Vincent S.R. Nitric oxide neurons and neurotransmission. Prog Neurobiol 2009, 90:246-255.
56. Nijs J., Van de Velde B., De Meirleir K. Pain in patients with chronic fatigue syndrome: does nitric oxide trigger central sensitisation?. Med Hypotheses 2005, 64:558-562.
57. Kumar A., Garg R., Kumar P. Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome. Pharmacol Rep 2008, 60:664-672.
58. Gupta A., Vij G., Chopra K. Possible role of oxidative stress and immunological activation in mouse model of chronic fatigue syndrome and its attenuation by olive extract. J Neuroimmunol 2010, 226:3-7.
59. Schwartz M., Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: the missing link between health and disease. Mol Psychiatry 2010, 15:342-354.
60. Soscia S.J., Kirby J.E., Washicosky K.J., Tucker S.M., Ingelsson M., Hyman B., et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010, 5:e9505.
61. Banks W.A., Kastin A.J., Ehrensing C.A. Blood-borne interleukin-1 alpha is transported across the endothelial blood-spinal cord barrier of mice. J Physiol 1994, 479(Pt 2):257-264.
62. Pan W., Kastin A.J. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout mice. Exp Neurol 2002, 174:193-200.
63. Pachter J.S., de Vries H.E., Fabry Z. The blood-brain barrier and its role in immune privilege in the central nervous system. J Neuropathol Exp Neurol 2003, 62:593-604.
64. Engelhardt B., Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol 2009, 31:497-511.
65. Henry C.J., Huang Y., Wynne A.M., Godbout J.P. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immun 2009, 23:309-317.
66. Mitchell K., Yang H.Y., Berk J.D., Tran J.H., Iadarola M.J. Monocyte chemoattractant protein-1 in the choroid plexus: a potential link between vascular pro-inflammatory mediators and the CNS during peripheral tissue inflammation. Neuroscience 2009, 158:885-895.
67. Natelson B.H., Cohen J.M., Brassloff I., Lee H.J. A controlled study of brain magnetic resonance imaging in patients with the chronic fatigue syndrome. J Neurol Sci 1993, 120:213-217.
68. de Lange F.P., Kalkman J.S., Bleijenberg G., Hagoort P., van der Meer J.W., Toni I. Gray matter volume reduction in the chronic fatigue syndrome. Neuroimage 2005, 26:777-781.
69. de Lange F.P., Koers A., Kalkman J.S., Bleijenberg G., Hagoort P., van der Meer J.W., et al. Increase in prefrontal cortical volume following cognitive behavioural therapy in patients with chronic fatigue syndrome. Brain 2008, 131:2172-2180.
70. Prohovnik I., Smith G., Sackeim H.A., Mayeux R., Stern Y. Gray-matter degeneration in presenile Alzheimer's disease. Ann Neurol 1989, 25:117-124.
71. Thomas M., Smith A. An investigation into the cognitive deficits associated with chronic fatigue syndrome. Open Neurol J 2009, 3:13-23.
72. Clark I.A., Budd A.C., Alleva L.M. Sickness behaviour pushed too far-the basis of the syndrome seen in severe protozoal, bacterial and viral diseases and post-trauma. Malar J 2008, 7:208.
73. Butler M.P., O'Connor J.J., Moynagh P.N. Dissection of tumor-necrosis factor-alpha inhibition of long-term potentiation (LTP) reveals a p38 mitogen-activated protein kinase-dependent mechanism which maps to early-but not late-phase LTP. Neuroscience 2004, 124:319-326.
74. Cumiskey D., Pickering M., O'Connor J.J. Interleukin-18 mediated inhibition of LTP in the rat dentate gyrus is attenuated in the presence of mGluR antagonists. Neurosci Lett 2007, 412:206-210.
75. Sharpe M., Hawton K., Clements A., Cowen P.J. Increased brain serotonin function in men with chronic fatigue syndrome. Bmj 1997, 315:164-165.
76. Cleare A.J., Messa C., Rabiner E.A., Grasby P.M. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [11C]WAY-100635. Biol Psychiatry 2005, 57:239-246.
77. Mancuso C., Navarra P., Preziosi P., oxide Roles of nitric, monoxide carbon and hydrogen sulfide in the regulation of the hypothalamic-pituitary-adrenal axis. J Neurochem 2010, 113:563-575.
78. Brown G.C. Nitric oxide and neuronal death. Nitric Oxide 2010, 2010:12.
79. Bennett M.R. Synapse regression in depression: the role of 5-HT receptors in modulating NMDA receptor function and synaptic plasticity. Aust N Z J Psychiatry 2010, 44:301-308.
80. Lindqvist D., Janelidze S., Hagell P., Erhardt S., Samuelsson M., Minthon L., et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009, 66:287-292.
81. Matsuda Y., Matsui T., Kataoka K., Fukada R., Fukuda S., Kuratsune H., et al. A two-year follow-up study of chronic fatigue syndrome comorbid with psychiatric disorders. Psychiatry Clin Neurosci 2009, 63:365-373.
82. Vercoulen J.H., Swanink C.M., Zitman F.G., Vreden S.G., Hoofs M.P., Fennis J.F., et al. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996, 347:858-861.
83. Horikawa H., Kato T.A., Mizoguchi Y., Monji A., Seki Y., Ohkuri T., et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1306-1316.
84. Gaab J., Rohleder N., Heitz V., Engert V., Schad T., Schurmeyer T.H., et al. Stress-induced changes in LPS-induced pro-inflammatory cytokine production in chronic fatigue syndrome. Psychoneuroendocrinology 2005, 30:188-198.
85. Van Den Eede F., Moorkens G., Van Houdenhove B., Cosyns P., Claes S.J. Hypothalamic-pituitary-adrenal axis function in chronic fatigue syndrome. Neuropsychobiology 2007, 55:112-120.
86. Blockmans D., Persoons P., Van Houdenhove B., Lejeune M., Bobbaers H., et al. Combination therapy with hydrocortisone and fludrocortisone does not improve symptoms in chronic fatigue syndrome: a randomized, placebo-controlled, double-blind, crossover study. Am J Med 2003, 114:736-741.
87. Heim C., Newport D.J., Heit S., Graham Y.P., Wilcox M., Bonsall R., et al. Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. Jama 2000, 284:592-597.
88. Rohleder N., Schommer N.C., Hellhammer D.H., Engel R., Kirschbaum C. Sex differences in glucocorticoid sensitivity of proinflammatory cytokine production after psychosocial stress. Psychosom Med 2001, 63:966-972.
89. Rohleder N., Wolf J.M., Piel M., Kirschbaum C. Impact of oral contraceptive use on glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. Psychoneuroendocrinology 2003, 28:261-273.
90. Price J.R., Mitchell E., Tidy E., Hunot V. Cognitive behaviour therapy for chronic fatigue syndrome in adults. Cochrane Database Syst Rev 2008, 16:CD001027.
91. Leone S.S., Huibers M.J., Kant I., van Amelsvoort L.G., van Schayck C.P., Bleijenberg G., et al. Long-term efficacy of cognitive-behavioral therapy by general practitioners for fatigue: a 4-year follow-up study. J Psychosom Res 2006, 61:601-607.
92. Maes M., Twisk F.N. Chronic fatigue syndrome: la bete noire of the Belgian health care system. Neuro Endocrinol Lett 2009, 30:300-311.
93. Twisk F.N., Maes M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol Lett 2009, 30:284-299.
94. Nunez M., Fernandez-Sola J., Nunez E., Fernandez-Huerta J.M., Godas-Sieso T., Gomez-Gil E., et al. Health-related quality of life in patients with chronic fatigue syndrome: group cognitive behavioural therapy and graded exercise versus usual treatment. A randomised controlled trial with 1 year of follow-up. Clin Rheumatol 2011, p. 15.
95. White P., Goldsmith K., Johnson A., Potts L., Walwyn R., Decesare J., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet 2011, p. 17.
96. Petersen A.M., Pedersen B.K. The anti-inflammatory effect of exercise. J Appl Physiol 2005, 98:1154-1162.
97. Garrod R., Ansley P., Canavan J., Jewell A. Exercise and the inflammatory response in chronic obstructive pulmonary disease (COPD)--Does training confer anti-inflammatory properties in COPD?. Med Hypotheses 2007, 68:291-298.
98. Mathur N., Pedersen B.K. Exercise as a mean to control low-grade systemic inflammation. Mediators Inflamm 2008, 2008:109502.
99. Adams G.R., Zaldivar F.P., Nance D.M., Cooper D.M. Exercise and leukocyte interchange among central circulation, lung, spleen, and muscle. Brain Behav Immun 2011, 14:14.
100. Ostrowski K., Rohde T., Asp S., Schjerling P., Pedersen B.K. Pro- and anti-inflammatory cytokine balance in strenuous exercise in humans. J Physiol 1999, 515(Pt 1):287-291.
101. Pedersen B.K., Ostrowski K., Rohde T., Bruunsgaard H. The cytokine response to strenuous exercise. Can J Physiol Pharmacol 1998, 76:505-511.
102. Cooper D.M., Radom-Aizik S., Schwindt C., Zaldivar F. Dangerous exercise: lessons learned from dysregulated inflammatory responses to physical activity. J Appl Physiol 2007, 103:700-709.
103. Tobinick E. Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother 2010, 10:985-1002.
104. Tobinick E.L., Chen K., Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes 2009, 2:28.
105. Reynolds K.J., Vernon S.D., Bouchery E., Reeves W.C. The economic impact of chronic fatigue syndrome. Cost Eff Resour Alloc 2004, 2:4.